Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection

Pien van Paassen*, Maartje Dijkstra, Holly L. Peay, Casper Rokx, Annelies Verbon, Peter Reiss, Jan M. Prins, Gail E. Henderson, Stuart Rennie, Pythia T. Nieuwkerk, Godelieve J. de Bree*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
16 Downloads (Pure)


Background: People who initiate antiretroviral therapy (ART) during acute HIV infection are potential candidates for HIV cure-related clinical trials, as early ART reduces the size of the HIV reservoir. These trials, which may include ART interruption (ATI), might involve potential risks. We explored knowledge and perception of HIV cure and willingness to participate in cure-related trials among participants of the Netherlands Cohort Study on Acute HIV infection (NOVA study), who started antiretroviral therapy immediately after diagnosis of acute HIV infection. Methods: We conducted 20 in-depth qualitative interviews with NOVA study participants between October–December 2018. Data were analyzed thematically, using inductive and iterative coding techniques. Findings: Most participants had limited knowledge of HIV cure and understood HIV cure as complete eradication of HIV from their bodies. HIV cure was considered important to most participants, mostly due to the stigma surrounding HIV. More than half would consider undergoing brief ATI during trial participation, but only one person considered extended ATI. Viral rebound and increased infectiousness during ATI were perceived as large concerns. Participants remained hopeful of being cured during trial participation, even though they were informed that no personal medical benefit was to be expected. Interpretation: Our results highlight the need for thorough informed consent procedures with assessment of comprehension and exploration of personal motives prior to enrollment in cure-related trials. Researchers might need to moderate their expectations about how many participants will enroll in a trial with extended ATI.

Original languageEnglish
Article number100072
JournalJournal of Virus Eradication
Issue number2
Publication statusPublished - Jun 2022

Bibliographical note

Funding Information:
The authors have no financial or proprietary interests in any material discussed in this article. GdB received honoraria to her institution for scientific advisory board participations for Gilead Sciences and speaker fees from Gilead Sciences. PR received grants from ViiV Healthcare, Gilead Sciences and Merck and participated in a Data Safety Monitoring Board, the honoraria are paid to the institution. CR received grants from Gilead, ViiV, Merck and JJ and payments or honoraria from Gilead and ViiV for viral education.

Funding Information:
This research was funded by Gilead Sciences, funding number CO-NL-276-422.

Publisher Copyright:
© 2022 The Authors


Dive into the research topics of 'Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection'. Together they form a unique fingerprint.

Cite this